BR0314640A - Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida - Google Patents

Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida

Info

Publication number
BR0314640A
BR0314640A BR0314640-5A BR0314640A BR0314640A BR 0314640 A BR0314640 A BR 0314640A BR 0314640 A BR0314640 A BR 0314640A BR 0314640 A BR0314640 A BR 0314640A
Authority
BR
Brazil
Prior art keywords
active ingredient
hepatitis
glycosylceramide
alpha
virus inhibitor
Prior art date
Application number
BR0314640-5A
Other languages
English (en)
Inventor
Isao Serizawa
Kazuo Ushida
Nousuke Nishi
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Publication of BR0314640A publication Critical patent/BR0314640A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

"INIBIDOR DE VìRUS DE HEPATITE C COMPREENDENDO, COMO UM INGREDIENTE ATIVO, ALFA-GLICOSILCERAMIDA". A presente invenção refere-se a um inibidor do crescimento do vírus de hepatite C humana compreendendo, como um ingrediente ativo, <244>- glicosilceramida usada para pacientes infectados com os vírus anteriormente mencionados. Este inibidor do vírus da hepatite C compreende, como um ingrediente ativo, um composto representado pela fórmula (I) ou um seu sal ou um solvato seu.
BR0314640-5A 2002-09-20 2003-09-18 Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida BR0314640A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002275466 2002-09-20
PCT/JP2003/011908 WO2004026318A1 (ja) 2002-09-20 2003-09-18 α-グリコシルセラミドを有効成分とするＣ型肝炎ウイルス抑制剤

Publications (1)

Publication Number Publication Date
BR0314640A true BR0314640A (pt) 2005-08-02

Family

ID=32025033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314640-5A BR0314640A (pt) 2002-09-20 2003-09-18 Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida

Country Status (10)

Country Link
US (1) US20050159365A1 (pt)
EP (1) EP1541153A1 (pt)
JP (1) JPWO2004026318A1 (pt)
KR (1) KR20050062551A (pt)
CN (1) CN1681519A (pt)
AU (1) AU2003266530A1 (pt)
BR (1) BR0314640A (pt)
CA (1) CA2499265A1 (pt)
TW (1) TW200412980A (pt)
WO (1) WO2004026318A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051156A1 (en) * 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
CA2441893C (en) 2001-03-26 2015-01-20 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20080145931A1 (en) 2004-10-07 2008-06-19 Argos Therapeutics, Inc. Mature Dendritic Cell Compositions and Methods of Culturing Same
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
MX337936B (es) * 2010-08-04 2016-03-29 Bristol Myers Squibb Co Compuestos inhibidores del virus de la hepatitis c.
CN105461681A (zh) * 2014-09-05 2016-04-06 中国科学院生态环境研究中心 具有抗肿瘤活性的krn7000类似物及合成方法
CN106674297A (zh) * 2015-11-11 2017-05-17 中国科学院生态环境研究中心 具有抗癌活性的新型krn7000类似物及合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0559081A (ja) * 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pt) * 1992-07-16 1995-11-01 Kirin Brewery
JPH08109134A (ja) * 1994-10-11 1996-04-30 Sanwa Kagaku Kenkyusho Co Ltd 細胞変成抑制並びに臓器毒性軽減剤

Also Published As

Publication number Publication date
EP1541153A1 (en) 2005-06-15
US20050159365A1 (en) 2005-07-21
TW200412980A (en) 2004-08-01
CA2499265A1 (en) 2004-04-01
CN1681519A (zh) 2005-10-12
KR20050062551A (ko) 2005-06-23
WO2004026318A1 (ja) 2004-04-01
AU2003266530A1 (en) 2004-04-08
JPWO2004026318A1 (ja) 2006-01-12

Similar Documents

Publication Publication Date Title
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
UY27333A1 (es) Nucleótidos 4` sustituidos
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
EA200900156A1 (ru) Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
EA200500846A1 (ru) Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2&#39;,4&#39; sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
TW200630344A (en) Tetracyclic indole derivatives as antiviral agents
BR0315493A (pt) Combinações de ariloxifenoxipropionatos e agentes de segurança e seu uso para aumentar o controle de ervas daninhas
BRPI0509795A (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso do composto ou sal farmacologicamente aceitável do mesmo, e, método para promover osteogênese, supressão de ressorção óssea e/ou melhoramento da densidade óssea
WO2006122011A3 (en) Thiazole compounds and methods of use
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
EA200500610A1 (ru) Композиция для лечения инфекции, вызываемой вирусами семейств flaviviridae
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
BRPI0415555A (pt) composição fungicida e método para controle de doenças nas plantas
CY1119809T1 (el) Μυκητοκτονος συνθεση και μεθοδος για την καταπολεμηση φυτικης ασθενειας
NO20052908D0 (no) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
BR112022001866A2 (pt) Derivados de amida híbridos de anfotericina b
NO20082727L (no) Salter av 9-oksoakridin-10-eddiksyre med 1-alkylamino-1-deoksypolyoler
EA200100143A1 (ru) Фосфорорганические соединения и их применение
BRPI0406875A (pt) Derivados de monossacarìdeo de avermectina tendo propriedades pesticidas
BR0215067A (pt) Piridoquinoxalinas antivirais

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]